Successful Treatment of Vancomycin-Resistant Enterococcus species Bone and Joint Infection with Daptomycin Plus Beta Lactam Agents
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bone and joint infections (BJI) caused by vancomycin-resistant Enterococcus spp. (VRE) are difficult to treat due to limited antibiotic options. Although linezolid can be used for VRE treatment, it is often discontinued due to time-dependent bone marrow suppression. Daptomycin, a lipopeptide antibiotic agent with rapid bactericidal activity, is another available therapeutic option for VRE infections. We report a case of VRE BJI successfully treated with a high dose of daptomycin plus β-lactam agents. An 84-year-old man received linezolid for the treatment of VRE BJI. After 2 weeks of therapy, the patient experienced bleeding events associated with linezolid-induced bone marrow toxicity and linezolid was discontinued. Next, high-dose daptomycin therapy combined with a β-lactam agent was selected to treat the remaining VRE BJI. During daptomycin treatment, microbiological eradication was achieved, and the patient clinically improved without evidence of adverse events. We highlight the need for daptomycin use for the treatment of VRE infections, especially in cases where linezolid is ineffective.
Abstract
Bone and joint infections (BJI) caused by vancomycin-resistant Enterococcus spp. (VRE) are difficult to treat due to limited antibiotic options. Although linezolid can be used for VRE treatment, it is often discontinued due to time-dependent bone marrow suppression. Daptomycin, a lipopeptide antibiotic agent with rapid bactericidal activity, is another available therapeutic option for VRE infections. We report a case of VRE BJI successfully treated with a high dose of daptomycin plus β-lactam agents. An 84-year-old man received linezolid for the treatment of VRE BJI. After 2 weeks of therapy, the patient experienced bleeding events associated with linezolid-induced bone marrow toxicity and linezolid was discontinued. Next, high-dose daptomycin therapy combined with a β-lactam agent was selected to treat the remaining VRE BJI. During daptomycin treatment, microbiological eradication was achieved, and the patient clinically improved without evidence of adverse events. We highlight the need for daptomycin use for the treatment of VRE infections, especially in cases where linezolid is ineffective.
참고문헌 (20)
- Tande AJ, "Clinical characteristics and outcomes of prosthetic joint infection caused by small colony variant staphylococci", mBio, 5, pp.e01910-4~ (2014)
- Trouillet-Assant S, "Adaptive processes of Staphylococcus aureus isolates during the progression from acute to chronic bone and joint infections in patients", Cell Microbiol, 18, pp.1405~1414 (2016)
- 정희진, "Clinical Guidelines for the Antimicrobial Treatment of Bone and Joint Infections in Korea", Infection and Chemotherapy, 46(2), pp.125~138 (2014), 대한감염학회
- Hashemian SMR, "Linezolid : a review of its properties, function, and use in critical care", Drug Des Devel Ther, 12, pp.1759~1767 (2018)
- Dhand A, "Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia", Clin Ther, 36, pp.1303~1316 (2014)
- Satlin MJ, "Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute", Clin Infect Dis, 70, pp.1240~1246 (2020)
- Chuang YC, "A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections", Sci Rep, 8, pp.1632~ (2018)
- Baddour LM, "Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association", Circulation, 132, pp.1435~1486 (2015)
- Montange D, "Penetration of daptomycin into bone and synovial fluid in joint replacement", Antimicrob Agents Chemother, 58, pp.3991~3996 (2014)
- Gerson SL, "Hematologic effects of linezolid : summary of clinical experience", Antimicrob Agents Chemother, 46, pp.2723~2726 (2002)
- Bernstein WB, "Mechanisms for linezolid-induced anemia and thrombocytopenia", Ann Pharmacother, 37, pp.517~520 (2003)
- Britt NS, "Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection : a national cohort study of veterans affairs patients", Clin Infect Dis, 61, pp.871~878 (2015)
- Shi C, "Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia : an updated systematic review and metaanalysis", J Glob Antimicrob Resist, 21, pp.235~245 (2020)
- Avery LM, "Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia : It is time to change the breakpoint", Clin Infect Dis, 68, pp.1650~1657 (2019)
- Liu C, "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children", Clin Infect Dis, 52, pp.e18~55 (2011)
- Beenken KE, "Mutation of sarA in Staphylococcus aureus limits biofilm formation", Infect Immun, 71, pp.4206~4211 (2003)
- Butterfield JM, "Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis", Antimicrob Agents Chemother, 57, pp.864~872 (2013)
- Vilay AM, "Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis", Crit Care Med, 39, pp.19~25 (2011)
- Jahanbakhsh S, "Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in vitro biofilm model", Antimicrob Agents Chemother, 64, pp.e02074-19~ (2020)
- Jorgensen SCJ, "Daptomycin plus β-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections : a retrospective, comparative cohort study", Clin Infect Dis, 71, pp.1~10 (2020)